source
- Scribe Therapeutics upsizes IPO to $128.7 million to fund lipid-lowering gene therapyScribe Therapeutics announced pricing its initial public offering at $128.7 million, surpassing the $96 million target it had set earlier in the week. The company sold 8.6 million shares at $15 ea…
- FDA advisory panel recommends adding peptides BPC-157 and KPV to bulk compounding listAn FDA advisory committee voted 8-6, with one abstention, to recommend that two experimental peptides – BPC-157 for ulcerative colitis and KPV for wound and inflammatory conditions – be placed on t…